Alpha1-antitrypsin review

Clinics in Chest Medicine

Volumn 35, Issue 1, 2014, Pages 39-50

  Stockley, Robert A ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Alpha1 antitrypsin deficiency; Emphysema; Genetics; Neutrophils; Therapy

Indexed keywords

ALPHA1-ANTITRYPSIN DEFICIENCY; EMPHYSEMA; GENETICS; NEUTROPHILS; THERAPY;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; GENETIC THERAPY; HUMANS; PHENOTYPE; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; SMOKING;

EID: 84893812809     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.10.001     Document Type: Review

References (90)

1. Laurell C., Eriksson S. The electrophoretic alpha 1-globulin pattern of serum in alpha 1-antitrypsin deficiency. Scand J Clin Lab Invest 1963, 15:132-140.
2. Senior R.M., Tegner H., Kuhn C., et al. The induction of pulmonary emphysema with human leukocyte elastase. Am Rev Respir Dis 1977, 116(3):469-475.
3. Kao R.C., Wehner N.G., Skubitz K.M., et al. Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. JClin Invest 1988, 82(6):1963-1973.
4. Dickens J.A., Lomas D.A. Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis. Drug Des Devel Ther 2011, 5:391-405.
5. Matheson N.R., Gibson H.L., Hallewell R.A., et al. Recombinant DNA-derived forms of human alpha 1-proteinase inhibitor. Studies on the alanine 358 and cysteine 358 substituted mutants. JBiol Chem 1986, 261(22):10404-10409.
6. Lomas D.A., Evans D.L., Finch J.T., et al. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992, 357(6379):605-607.
7. Seersholm N., Kok-Jensen A., Dirksen A. Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases. Thorax 1994, 49(7):695-698.
8. Seersholm N., Kok-Jensen A. Clinical features and prognosis of life time non-smokers with severe alpha 1-antitrypsin deficiency. Thorax 1998, 53(4):265-268.
9. Campos M.A., Alazemi S., Zhang G., et al. Clinical characteristics of subjects with symptoms of alpha1-antitrypsin deficiency older than 60 years. Chest 2009, 135(3):600-608.
10. Rodriguez-Cintron W., Guntupalli W.K., Fraire A.E. Bronchiectasis and homozygous (P1ZZ) alpha 1-antitrypsin deficiency in a young man. Thorax 1995, 50(4):424-425.
11. Parr D.G., Stoel B.C., Stolk J., et al. Pattern of emphysema distribution in α-1-antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med 2004, 170(11):1172-1178.
12. Piras B., Ferrarotti I., Lara B., et al. Clinical phenotypes of Italian and Spanish patients with alpha-1-antitrypsin deficiency. Eur Respir J 2013, 42(1):54-64.
13. Holme J., Stockley R.A. Radiologic and clinical features of COPD patients with discordant pulmonary physiology: lessons from a-1-antitrypsin deficiency. Chest 2007, 132:909-915.
14. Wood A.M., Needham M., Simmonds M.J., et al. Phenotypic differences in alpha 1 antitrypsin deficient sibling pairs may relate to genetic variation. COPD 2008, 5:353-359.
15. Dowson L.J., Guest P.J., Stockley R.A. Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med 2001, 164:1805-1809.
16. Dawkins P.A., Dawkins C.L., Wood A.M., et al. Rate of progression of lung function impairment in alpha-1-antitrypsin deficiency. Eur Respir J 2009, 33:1338-1344.
17. Tanash H.A., Nilsson P.M., Nilsson J.A., et al. Survival in severe alpha-1-antitrypsin deficiency (Pi ZZ). Respir Res 2010, 11:44.
18. Bernspang E., Wollmer P., Sveger T., et al. Lung function in 30-year-old alpha-1-antitrypsin-deficient individuals. Respir Med 2009, 103(6):861-865.
19. Holme J., Stockley J.A., Stockley R.A. Age related development of respiratory abnormalities in non-index a-1 antitrypsin deficient studies. Respir Med 2013, 107(3):387-393.
20. Parr D.G., Stoel B.C., Stolk J., et al. Validation of computed tomographic lung densitometry for monitoring emphysema in α-1-antitrypsin deficiency. Thorax 2006, 61:485-490.
21. Needham M., Stockley R.A. Exacerbations in α-1-antitrypsin deficiency. Eur Respir J 2005, 25:992-1000.
22. Corda L., Bertella E., La Piana G.E., et al. Inhaled corticosteroids as additional treatment in alpha-1-antitrypsin-deficiency-related COPD. Respiration 2008, 76(1):61-68.
23. Tanash H.A., Riise G.C., Hansson L., et al. Survival benefit of lung transplantation in individuals with severe alpha1-anti-trypsin deficiency (PiZZ) and emphysema. JHeart Lung Transplant 2011, 30(12):1342-1347.
24. Stone H., Edgar R.G., Stockley R.A. Lung Transplantation in Alpha-1-Antitrypsin Deficiency. British Q19 Thoracic Society Winter Meeting. Thorax 2012, 67(suppl 2):A99.
25. Fishman A., Martinez F., Naunheim K., et al. Arandomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. NEngl J Med 2003, 348(21):2059-2073.
26. Morrison H.M., Kramps J.A., Burnett D., et al. Lung lavage fluid from patients with alpha1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profile. Clin Sci 1987, 72:373-381.
27. Mahadeva R., Atkinson C., Li Z., et al. Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic invivo. Am J Pathol 2005, 166(2):377-386.
28. Hubbard R.C., Fells G., Gadek J., et al. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. JClin Invest 1991, 88(3):891-897.
29. Woolhouse I.S., Bayley D.L., Stockley R.A. Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of α1-antitrypsin deficiency and the role of leukotriene B4 and interleukin 8. Thorax 2002, 57:709-714.
30. Liou T.G., Campbell E.J. Quantum proteolysis resulting from release of single granules by human neutrophils: a novel, nonoxidative mechanism of extracellular proteolytic activity. JImmunol 1996, 157(6):2624-2631.
31. Parmar J.S., Mahadeva R., Reed B.J., et al. Polymers of alpha(1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. Am J Respir Cell Mol Biol 2002, 26(6):723-730.
32. Gooptu B., Ekeowa U.I., Lomas D.A. Mechanisms of emphysema in alpha1-antitrypsin deficiency: molecular and cellular insights. Eur Respir J 2009, 34(2):475-488.
33. Stockley R.A. Long-term intervention studies: α1-antitrypsin substitution. Long-term intervention in chronic obstructive pulmonary disease 2005, 445-462. Marcel Dekker, NewYork. R.A. Pauwels, D.S. Postma, S.T. Weiss (Eds.).
34. Dhami R., Zay K., Gilks B., et al. Pulmonary epithelial expression of human alpha1-antitrypsin in transgenic mice results in delivery of alpha1-antitrypsin protein to the interstitium. JMol Med (Berl) 1999, 77(4):377-385.
35. Morissette M.C., Parent J., Milot J. Alveolar epithelial and endothelial cell apoptosis in emphysema: what we know and what we need to know. Int J Chron Obstruct Pulmon Dis 2009, 4:19-31.
36. Sullivan A.L., Stockley R.A. Proteinases and COPD. Recent Advances in the Pathophysiology of COPD 2004, 75-99. Birkhäuser Verlag Basel/Switzerland. T.T. Hansel, P.J. Barnes (Eds.).
37. McAloon C.J., Wood A.M., Gough S.C., et al. Matrix metalloprotease polymorphisms are associated with gas transfer in alpha 1 antitrypsin deficiency. Ther Adv Respir Dis 2009, 3:23-30.
38. Kim W.J., Wood A.M., Barker A.F., et al. Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency. Respir Res 2012, 13(1):16.
39. Sapey E., Wood A.M., Ahmad A., et al. TNF alpha rs361525 polymorphism is associated with increased local production and downstream inflammation in COPD. Am J Respir Crit Care Med 2010, 182(2):192-199.
40. Fregonese L., Stolk J., Frants R.R., et al. Alpha-1 antitrypsin Null mutations and severity of emphysema. Respir Med 2008, 102(6):876-884.
41. Campbell E.J., Campbell M.A., Boukedes S.S., et al. Quantum proteolysis by neutrophils: implications for pulmonary emphysema in alpha 1-antitrypsin deficiency. JClin Invest 1999, 104(3):337-344.
42. Weitz J.I., Silverman E.K., Thong B., et al. Plasma levels of elastase-specific fibrinopeptides correlate with proteinase inhibitor phenotype. Evidence for increased elastase activity in subjects with homozygous and heterozygous deficiency of alpha 1-proteinase inhibitor. JClin Invest 1992, 89(3):766-773.
43. Sorheim I.C., Bakke P., Gulsvik A., et al. Alpha(1)-antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. Chest 2010, 138(5):1125-1132.
44. Stockley R.A. Alpha1-antitrypsin phenotypes in cor pulmonale due to chronic obstructive airways disease. QJ Med 1979, 191:419-428.
45. Seersholm N., Wilcke J.T., Kok-Jensen A., et al. Risk of hospital admission for obstructive pulmonary disease in alpha(1)-antitrypsin heterozygotes of phenotype PiMZ. Am J Respir Crit Care Med 2000, 161(1):81-84.
46. Dahl M., Tybjaerg-Hansen A., Lange P., et al. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: a longitudinal study of the general population. Ann Intern Med 2002, 136(4):270-279.
47. Dahl M., Hersh C.P., Ly N.P., et al. The protease inhibitor PI*S allele and COPD: a meta-analysis. Eur Respir J 2005, 26(1):67-76.
48. Holme J., Stockley R.A. CT Scan appearance, densitometry, and health status in protease inhibitor SZ α1-antitrypsin deficiency. Chest 2009, 136(5):1284-1290.
49. Stockley R.A., Stolk J., Dirksen A. Alpha-1-antitrypsin deficiency: the European experience. COPD 2013, 10(Suppl 1):50-53.
50. Cook L., Burdon J.G., Brenton S., et al. Kinetic characterisation of alpha-1-antitrypsin F as an inhibitor of human neutrophil elastase. Pathology 1996, 28(3):242-247.
51. Gadek J.E., Klein H.G., Holland P.V., et al. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. JClin Invest 1981, 68(5):1158-1165.
52. Stockley R.A., Bayley D.L., Unsal I., et al. The effect of augmentation therapy on bronchial inflammation in α1-antitrypsin deficiency. Am J Respir Crit Care Med 2002, 165:1494-1498.
53. Schluchter M.D., Stoller J.K., Barker A.F., et al. Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 2000, 161(3 Pt 1):796-801.
54. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998, 158(1):49-59.
55. Seersholm N., Wencker M., Banik N., et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997, 10(10):2260-2263.
56. Wencker M., Fuhrmann B., Banik N., et al. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest 2001, 119(3):737-744.
57. Chapman K.R., Stockley R.A., Dawkins C., et al. Augmentation therapy for alpha-1 antitrypsin deficiency: a meta-analysis. COPD 2009, 6(3):177-184.
58. Stolk J., Cooper B.G., Stoel B., et al. Retinoid treatment of emphysema in patients on the Alpha-1 International Registry. The REPAIR study: study design, methodology and quality control of study assessments. Ther Adv Respir Dis 2010, 4(6):319-332.
59. Dirksen A., Dijkman J.H., Madsen F., et al. Arandomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999, 160(5 Pt 1):1468-1472.
60. Dirksen A., Piitulainen E., Parr D.G., et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha-1-antitrypsin deficiency. Eur Respir J 2009, 33:1345-1353.
61. Parr D.G., Dirksen A., Piitulainen E., et al. Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study augmentation therapy in alpha-1-antitrypsin deficiency. Respir Res 2009, 10(1):75.
62. Stockley R.A., Parr D.G., Piitulainen E., et al. Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res 2010, 11:136.
63. Hay J.W., Robin E.D. Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease. Am J Public Health 1991, 81(4):427-433.
64. Stolk J., Camps J., Feitsma H., et al. Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor. Thorax 1995, 50(6):645-650.
65. Gorin A.B., Stewart P.A. Differential permeability of endothelial and epithelial barriers to albumin flux. JAppl Physiol Respir Environ Exerc Physiol 1979, 47(6):1315-1324.
66. Hill A.T., Campbell E.J., Bayley D.L., et al. Evidence for excessive bronchial inflammation during an acute exacerbation of COPD in patients with alpha-1-antitrypsin deficiency. Am J Respir Crit Care Med 1999, 160:1968-1975.
67. Vijayasaratha K., Stockley R.A. Reported and unreported exacerbations of COPD: analysis by diary cards. Chest 2008, 133:34-41.
68. International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema. 2010. ClinicalTrials.gov. NCT01217671.
69. Stockley R.A., Vogelmeier C., Miravitlles M. Augmentation therapy for alpha1-antitrypsin deficiency: towards a personalised approach. Orphanet Journal of Rare Diseases 2013, 8:149.
70. Pittelkow M.R., Smith K.C., Su W.P. Alpha-1-antitrypsin deficiency and panniculitis. Perspectives on disease relationship and replacement therapy. Am J Med 1988, 84(6A):80-86.
71. Morris H., Morgan M.D., Wood A.M., et al. ANCA-associated vasculitis is linked to carriage of the allele of alpha-1 antitrypsin and its polymers. Ann Rheum Dis 2011, 70(10):1851-1856.
72. Yu S.D., Gan J.C. Effects of progressive desialylation on the survival of human plasma alpha1-anti-trypsin in rat circulation. Int J Biochem 1978, 9(2):107-115.
73. Spencer L.T., Humphries J.E., Brantly M.L. Antibody response to aerosolized transgenic human alpha1-antitrypsin. NEngl J Med 2005, 352(19):2030-2031.
74. Blanchard V., Liu X., Eigel S., et al. N-glycosylation and biological activity of recombinant human alpha1-antitrypsin expressed in a novel human neuronal cell line. Biotechnol Bioeng 2011, 108(9):2118-2128.
75. Burrows J.A., Willis L.K., Perlmutter D.H. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc Natl Acad Sci U S A 2000, 97(4):1796-1801.
76. Teckman J.H. Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study. JPediatr Gastroenterol Nutr 2004, 39(1):34-37.
77. Mallya M., Phillips R.L., Saldanha S.A., et al. Small molecules block the polymerization of Z alpha1-antitrypsin and increase the clearance of intracellular aggregates. JMed Chem 2007, 50(22):5357-5363.
78. Lee C., Maeng J.S., Kocher J.P., et al. Cavities of alpha(1)-antitrypsin that play structural and functional roles. Protein Sci 2001, 10(7):1446-1453.
79. Flotte T.R., Trapnell B.C., Humphries M., et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther 2011, 22(10):1239-1247.
80. Cruz P.E., Mueller C., Cossette T.L., et al. Invivo post-transcriptional gene silencing of alpha-1 antitrypsin by adeno-associated virus vectors expressing siRNA. Lab Invest 2007, 87(9):893-902.
81. Mueller C.G., Hess E. Emerging functions of RANKL in lymphoid tissues. Front Immunol 2012, 3:261.
82. McNab G.L., Ahmad A., Mistry D., et al. Modification of gene expression and increase in α1-antitrypsin (α1-AT) secretion after homologous recombination in α1-AT-deficient monocytes. Hum Gene Ther 2007, 18:1171-1177.
83. De B.P., Heguy A., Hackett N.R., et al. High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol Ther 2006, 13(1):67-76.
84. Yusa K., Rashid S.T., Strick-Marchand H., et al. Targeted gene correction of alpha1-antitrypsin deficiency in induced pluripotent stem cells. Nature 2011, 478(7369):391-394.
85. Sinden N.J., Stockley R.A. Proteinase 3 activity insputum from subjects with alpha-1-antitrypsin deficiency and COPD. Eur Respir J 2013, 41(5):1042-1050.
86. Maden M. Retinoids have differing efficacies on alveolar regeneration in a dexamethasone-treated mouse. Am J Respir Cell Mol Biol 2006, 35(2):260-267.
87. Stolk J., Stockley R.A., Stoel B.C., et al. Randomized controlled trial for emphysema with a selective agonist of the gamma type retinoic acid receptor. Eur Respir J 2012, 40:306-312.
88. Shapiro S.D., Endicott S.K., Province M.A., et al. Marked longevity of human lung parenchymal elastic fibers deduced from prevalence of d-aspartate and nuclear weapons-related radiocarbon. JClin Invest 1991, 87(5):1828-1834.
89. Turino G.M., Lin Y.Y., He J., et al. Elastin degradation: an effective biomarker in COPD. COPD 2012, 9(4):435-438.
90. Carter R.I., Mumford R.A., Treonze K.M., et al. The fibrinogen cleavage product AαVal360, a specific marker of neutrophil elastase activity invivo. Thorax 2011, 66:686-691.